elemental iron (NovaFerrum®) — Competitive Intelligence Brief

elemental iron (NovaFerrum®) (elemental iron (NovaFerrum®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron supplement. Area: Hematology.

marketed Iron supplement Iron (Fe2+/Fe3+) — cofactor for hemoglobin and myoglobin synthesis Hematology Small molecule

Target snapshot

elemental iron (NovaFerrum®) (elemental iron (NovaFerrum®)) — University of Texas Southwestern Medical Center. Elemental iron replaces depleted iron stores and serves as a cofactor for hemoglobin synthesis, restoring oxygen-carrying capacity in iron-deficient patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
elemental iron (NovaFerrum®) TARGET	elemental iron (NovaFerrum®)	University of Texas Southwestern Medical Center	marketed	Iron supplement	Iron (Fe2+/Fe3+) — cofactor for hemoglobin and myoglobin synthesis
Ferric Pyrophosphate Liposomal	Ferric Pyrophosphate Liposomal	All India Institute of Medical Sciences	marketed	Iron supplement
F (ferrous sulphate)	F (ferrous sulphate)	Abdelwahed, Mai Mahmoud Mohamed, M.D.	marketed	Iron supplement	Iron (Fe2+) for hemoglobin and myoglobin synthesis
Treatment with oral sucrosomial iron	Treatment with oral sucrosomial iron	University of Rochester	marketed	Iron supplement (oral formulation)	Iron (Fe3+) absorption pathway
Sucrosomial Iron	Sucrosomial Iron	Cardiochirurgia E.H.	marketed	Iron supplement
Ferrous sulphate	Ferrous sulphate	University of Lausanne	marketed	Iron supplement	Iron (Fe2+) for hemoglobin and myoglobin synthesis
Iron protein succinylate oral solution	Iron protein succinylate oral solution	Lee's Pharmaceutical Limited	marketed	Iron supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron supplement class)

1. Tanabe Pharma Corporation · 4 drugs in this class
2. Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri · 2 drugs in this class
3. Universidade Federal Fluminense · 2 drugs in this class
4. Clinica Fabia Mater · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. Hatem AbuHashim · 1 drug in this class
7. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
8. Laboratoire Innotech International · 1 drug in this class
9. Lee's Pharmaceutical Limited · 1 drug in this class
10. Milton S. Hershey Medical Center · 1 drug in this class